Ive pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys. Reprod

Ive pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys. Reprod Toxicol. 2012;33(4):428?0. 35. Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, Zobel LR. Half-life serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical creation staff. Environ Overall health Perspect. 2007;115(9):1298?05.36. Hu W, Jones PD, Celius T, Giesy JP. Identification of genes conscious of PFOS using gene expression profiling. Approximativement Toxicol Pharmacol. 2005; 19(1):57?0. 37. Narimatsu S, Nakanishi R, Hanioka N, Saito K, Kataoka H. Characterization of inhibitory results of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes: concentrating on CYP2A6. Chem Biol Interact. 2011;194(2?):one hundred twenty?. 38. Andersen PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28559105 ME, Clewell third HJ, Tan YM, Butenhoff JL, Olsen GW. Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys robing the determinants of long plasma half-lives. Toxicology. 2006;227(one?):156?4. 39. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E(two) guards intestinal tumors from nonsteroidal anti-inflammatory druginduced regression in Apc(Min/+) mice. Cancer Res. 2002;62(2):403?. forty. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma advancement. Nat Med. 2004;10(3):245?. forty one. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, DuBois RN. Prostaglandin E(2) promotes colorectal adenoma expansion by using transactivation from the nuclear peroxisome proliferator-activated receptor delta. Most cancers Cell. 2004;6(3):285?5. 42. Vanden Heuvel J, Thompson J, Frame S, Gillies P. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and pure fatty acids: a comparison of human, mouse, and rat peroxisome proliferatoractivated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci. 2006;92(two):476?9. 43. Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, Sugimura T, Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp development in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res. 2003;sixty three(18):6090?. 44. Shipley JM, Hurst CH, Tanaka SS, DeRoos FL, Butenhoff JL, Seacat AM, Waxman DJ. trans-activation of PPARalpha and induction of PPARalpha focus on genes by perfluorooctane-based substances. Toxicol Sci. 2004;eighty(1):151?0. forty five. Ye L, Zhao B, Yuan K, Chu Y, Li C, Zhao C, Lian QQ, Ge RS. Gene expression profiling in fetal rat lung in the course of gestational perfluorooctane sulfonate exposure. Toxicol Lett. 2012;209(three):270?. forty six. Takacs ML, Abbott BD. Activation of mouse and human peroxisome proliferatoractivated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol Sci. 2007;95(1):108?seven. forty seven. Reasonable PA, Driscoll E, Mollenhauer MAM, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26043823 Bradshaw SG, Yun SH, Kannan K, Bossart GD, Keil DE, Peden-Adams MM. Outcomes of environmentally related amounts of perfluorooctane sulfonate on medical parameters and immunological capabilities in B6C3F1 mice. J Immunotoxicol. 2011;eight(1):seventeen?nine. Leupeptin hemisulfate Epub 2011 Jan 24 doi:103109/1547691X2010527868 2011, eight(one):17?9. 48. Oshio H, Abe T, Onogawa T, Ohtsuka H, Sato T, Ii T, Fukase K, Muto M, Katayose Y, Oikawa M, et al. Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2.